2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2146

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis in Anti-TNF-Naive Patients and Those Previously Exposed to Anti-TNF Therapy: 52-Week Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial with Subcutaneous Dosing
Abstract Number: 2844

Secukinumab Reduces the Burden of Nail and Skin Disease in Patients with Psoriasis and Patients with Psoriatic Arthritis: Results from Two Phase 3 Studies
Abstract Number: 2886

Secukinumab Safety and Tolerability in Patients with Active Psoriatic Arthritis and Psoriasis: Results from a Pooled Safety Analysis
Abstract Number: 974

Secukinumab Significantly Improves Signs and Symptoms of Active Ankylosing Spondylitis: 52-Week Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial with Subcutaneous Loading and Maintenance Dosing
Abstract Number: 2725

Secular Trends in Use of Disease Modifying Anti-Rheumatic Drugs for the Treatment of Rheumatoid Arthritis in the United States
Abstract Number: 1680

Selective JAK1 Inhibition with Filgotinib (GLPG0634) Decreases Plasma Markers of Inflammation and Joint Damage in Patients with Rheumatoid Arthritis
Abstract Number: 27

Self-Reported Sedentary Behavior in Patients with Rheumatoid Arthritis
Abstract Number: 1941

Senescent T-Cells Expedite RANKL-Dependent Bone Loss in Rheumatoid Arthritis
Abstract Number: 776

Sensitivity of Antinuclear Antibody By Immunofluorescence Testing for Detection of Anti-Ro/SSA Antibodies
Abstract Number: 1884

Sensitivity to Change of Nailfold Videocapillaroscopy and Relationship with Disease Progression
Abstract Number: 1715

Sensivity and Specificity of Clinical Criteria to Identify Patients in Ultrasound Remission in Psoriatic Arthritis
Abstract Number: 1536

Sensorineural Hearing Impairment and Subclinical Atherosclerosis in Rheumatoid Arthritis Patients without Traditional Cardiovascular Risk Factors
Abstract Number: 1692

Serious Infections in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study
Abstract Number: 3127

Serologic Diagnosis of Human Neuropsychiatric Lupus Using the Immunarray ICHIP®
Abstract Number: 635

Seronegative Sjögren’s Syndrome Is Associated with a Higher Frequency of Patient-Reported Neuropathic Pain: An Analysis of the Sjögren’s International Collaborative Clinical Alliance Cohort

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].